2019 Speaker Interviews


Beyond T Cell Immunotherapy

Shiladitya Sengupta, PhD, Principle Investigator, Engineering in Medicine, Brigham and Women’s Hospital, Harvard Medical School and Massachusetts Institute of Technology

Dr. Sengupta discusses his view on targeting different stromal cells such as macrophages and NK cells, along with his preference on using human down or mouse up approach for immunotherapy. He also mentions the status of his recent work on reporter nanoparticle that monitors its anticancer efficacy in real time to identify responders versus nonresponders early on for immunotherapy treatments.

Tipping the Balance Towards Success in a Phase 2b Recurrent GBM Trial: Overcoming the Tumor and its Microenvironment by Targeting the IL4R Using MDNA55

Fahar Merchant, PhD, President, CEO, Medicenna Therapeutics

Therapeutic Targeting of Trained Immunity

Mihai G. Netea, PhD, Professor, Internal Medicine, Radboud University Medical Center, The Netherlands

CAR Macrophage Immunotherapy: A New Frontier for Innate Immunity

Michael Klichinsky, PharmD, PhD, Co-Founder & VP, Discovery Research, Carisma Therapeutics